Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RAD51C R193* |
| Therapy | Niraparib + TNG348 |
| Indication/Tumor Type | ovarian cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51C R193* | ovarian cancer | sensitive | Niraparib + TNG348 | Preclinical - Pdx | Actionable | In a preclinical study, treatment with the combination of TNG348 and Zejula (niraparib) resulted in greater inhibition of tumor growth than either agent alone in a patient-derived xenograft (PDX) model of ovarian cancer harboring RAD51C R193* (PMID: 39886906). | 39886906 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39886906) | Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency. | Full reference... |